S 3604, the Public Health Nursing Act, establishes a $5 billion annual federal grant program (2026-2035) to expand public health nursing services. It provides funding to state, local, and territorial health departments to hire and train registered nurses, particularly in medically underserved areas with high rates of chronic disease, maternal mortality, or low-income populations. Funds cover nurse wages, training, medical supplies, and administrative costs, with priority given to applicants serving rural communities, health professional shortage areas, and populations requiring culturally appropriate care. Recipients must maintain their own funding levels for these services and cannot use grants to replace existing state/local spending.
This bill reauthorizes three existing rural health care grant programs under the Public Health Service Act through 2030, extending funding from the previous 2021-2025 period. It requires all funded projects to directly serve rural underserved populations and involve these communities in planning, development, and operations. The programs support rural clinics, health networks, and quality improvement initiatives to expand access to care in underserved areas. Funding will now continue through 2030, maintaining critical support for rural health providers.
The Choose Medicare Act would create a new Medicare Part E public health plan available in the individual, small group, and large group insurance markets. This plan would provide gold-level coverage with essential health benefits, including reproductive services, and would be offered through health insurance exchanges. The bill establishes premium rates based on market type and geographic area, and creates annual out-of-pocket cost limits starting in 2027 (initially set at $6,700 for 2027). It would directly affect individuals and employers seeking health coverage, particularly those currently in the individual market or small/large group plans who may choose this new public option.
HRES 835 is a symbolic resolution declaring gun violence a public health crisis in the United States. It urges federal agencies, particularly the Centers for Disease Control and Prevention (CDC), to apply a public health framework - including data collection, prevention research, and coordinated government action - to address gun violence. The resolution supports similar declarations already made by states and cities, and calls for the Surgeon General to issue a report on firearm violence prevention. As a non-binding resolution, it does not create new laws or allocate funding but aims to shift the national approach to gun violence as a preventable health issue.
This non-binding Senate resolution (SRES 389) condemns Secretary of Health and Human Services Robert F. Kennedy, Jr.'s actions dismissing the CDC's independent Advisory Committee on Immunization Practices and opposes Florida's 2025 policy rolling back school immunization requirements for children. It affirms that vaccines are critical for public health, preventable illness, and hospitalization reduction, and must be widely accessible at high community adoption rates. The resolution expresses the Senate's support for science-based vaccine policies, opposes politicizing medical recommendations, and emphasizes that vaccines should remain affordable and available through insurance and community settings like clinics and pharmacies. It does not create new laws but formally states the Senate's position against policies it views as endangering public health.
SRES 67 is a Senate resolution declaring racism a public health crisis in the United States. It cites documented racial health disparities - including lower life expectancy, higher maternal mortality, and disproportionate disease burdens among Black, American Indian, Alaska Native, and other minority communities - as meeting public health crisis criteria (affecting many, unfairly distributed, preventable, and lacking current solutions). The resolution calls for a nationwide strategy to dismantle systemic racism and address social determinants of health (like housing, education, and healthcare access), but it does not create new laws or funding. As a symbolic resolution, it aims to prompt government action rather than impose policy changes.
House Resolution 388 designates the first week of April as "Adolescent Immunization Action Week" to promote vaccination for teens and young adults. The resolution calls on communities, health providers, and organizations to support immunization efforts, particularly addressing vaccine misinformation and low uptake in rural and underserved areas. It does not create new laws or funding but encourages collaborative action to improve vaccination rates for adolescents.
This bill simplifies the approval process for biosimilar drugs - medicines that are highly similar to, but not identical to, existing biologic drugs. It amends the Public Health Service Act to clarify when biosimilars are deemed "interchangeable" with the original drug (allowing pharmacists to substitute them without a doctor's specific order), adjusts exclusivity periods for existing biosimilars, and sets a 60-day transition period after enactment. The bill also requires the FDA to update its guidance documents within 18 months to reflect these changes. This directly affects pharmaceutical companies developing biosimilars, the FDA in its review process, and ultimately patients seeking more affordable treatment options.
The MAPS Act requires the Secretary of Health and Human Services to update and maintain an Essential Medicines List including drugs critical for national security, public health emergencies, chronic conditions, and military readiness. It mandates annual risk assessments identifying supply chain vulnerabilities, particularly drugs sourced over 50% from high-risk foreign suppliers like China, and compiles data on manufacturing locations and shortages. The bill directs HHS to map U.S. pharmaceutical supply chains from raw materials to finished products, using data analytics to identify national security threats, and report findings annually to Congress. This directly affects federal agencies (HHS, Defense), drug manufacturers, and supply chain stakeholders through mandatory reporting and transparency requirements.
S 1489, the Anti-Racism in Public Health Act of 2025, establishes a National Center on Antiracism and Health within the CDC to address racial health disparities. It directly affects the CDC, public health researchers, state/local health agencies, and communities of color by requiring systematic research on structural racism's health impacts and funding for community-based antiracism initiatives. Key mechanisms include declaring racism a public health crisis, creating regional centers of excellence in minority communities, collecting disaggregated health data by race, ethnicity, and other demographics, and developing interventions to dismantle racist systems in healthcare. The bill mandates the CDC to produce public reports, coordinate with tribal entities, and standardize data collection to advance racial equity in public health.
